ArticleFish physiology and biochemistry2025
The gyk-foxq1 regulatory axis serves as a novel target and provides a breeding indicator for glucose homeostasis regulation in Micropterus salmoides.
Article in Fish physiology and biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Improving farmed fish carbohydrate utilization reduces the feed fish meal level and lessens water pollution. Herein, the effects of glycerol kinase (gyk) and forkhead box (fox)-q1 on Micropterus salmoides glucose homeostasis were investigated, and a growth-linked marker in gyk on a carbohydrate-rich diet was developed. The data showed that gyk and foxq1 expression is negatively correlated with plasma glucose level. Although gyk and foxq1 showed no effect on plasma triglyceride, cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, hepatic triglyceride, and muscular triglyceride content, positive regulation of insulin secretion, hepatic glycogen, and muscular glycogen level was observed. Overexpression and shRNA-mediated knockdown assays indicated that gyk and foxq1 positively regulate hepatic and muscular gene expression involved in triglyceride synthesis (fatty acid synthetase, acetyl-CoA carboxylase), glycolysis (phosphofructokinase, glucokinase), glycogen synthesis (glycogen synthase), and pentose phosphate pathway (glucose-6-phosphate dehydrogenase), but negatively regulate gluconeogenesis gene (phosphoenolpyruvate carboxykinase, glucose-6-phosphatase). In vitro, - 1652 ~ - 2056 bp was determined to be the core promoter sequence of gyk using progressive deletion. Luciferase activity showed that gyk promoter activity decreased following foxq1 binding site mutation in this sequence, and it was enhanced by foxq1 overexpression. Moreover, foxq1 inhibition attenuated hypoglycemia induced by gyk overexpression, and its suppression relieved the increase in gyk-mediated plasma glucose. Besides, an insertion-deletion marker located at rs16857996 in gyk was developed. Individuals without deletion (aaaac) of this site had higher body weight, full length, and body length. This regulatory axis provides a theoretical target and breeding indicator for increasing carbohydrate utilization and reducing the dietary fish meal in M. salmoides.
Indexed as
Identifiers
41212329What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.